Details :
RV001 (onilcamotide), peptide antigen against RhoC – is administered to patient through subcutaneous injection, encounters dendritic cells – type of white blood cell with regulatory functions in immune system – that capture, absorb and process RV00...
Details :
The safety profile of RV001 (onilcamotide) was considered excellent, and the DSMC concluded that the trial can continue without modifications and can significantly prevent or delay disease progression.
Details :
The objective of the study is to show that RV001 can significantly prevent or delay disease progression in these patients, something for which no standard therapy is available today.
Details :
RhoVac reported that as Covid-19 vaccinations are presently being rolled out in the age brackets of our study, some patients will have their RV001 treatment initiation deferred until after vaccination causing a delay in RhoVac's Phase IIb study.
Details :
BRaVac is a phase IIb randomized, placebo controlled and double-blind study, with the primary objective of evaluating if treatment with the drug candidate RV001 can prevent or limit the development of advanced prostate cancer after curative intent treatm...
Details :
RV001, is an immuno-oncologic drug that is presented to the immune system as an antigen, stimulating T-cells to identify and destroy cells that carry this protein, i.e. metastatic or metastatic potential cells.
Details :
The objective of the development of RV001 is to prevent/delay the recurrence of cancer and its progression to a metastatic state. If a clinical proof of concept is obtained in prostate cancer, several other cancer indications would also be candidates for...
Details :
The scientifically reviewed article reports that the treatment with RhoVac’s drug candidate RV001 was safe and well tolerated, and that a long-lasting immune response could be generated in the vast majority of patients.
Details :
The article will feature an elaboration on the mode of action of RV001, but also a discussion on the PSA data findings indicating possibilities of delaying disease progression, for which RhoVac’s currently ongoing phase IIb study is aimed at providing ...
Details :
First patient in the USA is included in RhoVac’s BRaVac study. BraVac is a randomized, placebo controlled and double-blind study which aims to evaluate if treatment with RV001 can prevent or limit the development of advanced prostate cancer after curat...
Reset All
